Grifols presents 'unique' Alzheimer's findings

16 July 2019

Spanish drugmaker Grifols (GRF: MC) has presented additional results from its AMBAR – Alzheimer management by albumin replacement – clinical trial.

The findings have been presented at Alzheimer's Association International Conference (AAIC) 2019 in Los Angeles and are in line with those presented at conferences in Europe in the last year.

Results presented earlier showed a statistically-significant reduction of 61% in disease progression in both primary efficacy endpoints, Alzheimer's disease assessment scale – cognitive, and Alzheimer's disease cooperative study – activities of daily living scales, in the cohort of moderate patients.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK